$74.4 Million is the total value of CAXTON CORP's 16 reported holdings in Q2 2022. The portfolio turnover from Q1 2022 to Q2 2022 was 100.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| RMGCU | Exit | RMG ACQUISITION CORP IIIunit 02/08/2026 | $0 | – | -11,000 | -100.0% | -0.14% | – |
| CVNA | Exit | CARVANA COcl a | $0 | – | -3,224 | -100.0% | -0.48% | – |
| PYPL | Exit | PAYPAL HLDGS INC | $0 | – | -3,538 | -100.0% | -0.51% | – |
| CDLX | Exit | CARDLYTICS INC | $0 | – | -8,543 | -100.0% | -0.58% | – |
| NFLX | Exit | NETFLIX INC | $0 | – | -1,484 | -100.0% | -0.69% | – |
| FB | Exit | META PLATFORMS INCcl a | $0 | – | -2,791 | -100.0% | -0.77% | – |
| CHTR | Exit | CHARTER COMMUNICATIONS INC Ncl a | $0 | – | -1,210 | -100.0% | -0.82% | – |
| WHR | Exit | WHIRLPOOL CORP | $0 | – | -3,843 | -100.0% | -0.83% | – |
| DIS | Exit | DISNEY WALT CO | $0 | – | -5,002 | -100.0% | -0.85% | – |
| CRM | Exit | SALESFORCE COM INC | $0 | – | -3,294 | -100.0% | -0.87% | – |
| FICO | Exit | FAIR ISAAC CORP | $0 | – | -1,715 | -100.0% | -1.00% | – |
| AMT | Exit | AMERICAN TOWER CORP NEW | $0 | – | -3,196 | -100.0% | -1.00% | – |
| MDLZ | Exit | MONDELEZ INTL INCcl a | $0 | – | -13,405 | -100.0% | -1.05% | – |
| MCO | Exit | MOODYS CORP | $0 | – | -2,567 | -100.0% | -1.08% | – |
| MA | Exit | MASTERCARD INCORPORATEDcl a | $0 | – | -2,438 | -100.0% | -1.08% | – |
| V | Exit | VISA INC | $0 | – | -3,931 | -100.0% | -1.08% | – |
| TDG | Exit | TRANSDIGM GROUP INC | $0 | – | -1,391 | -100.0% | -1.13% | – |
| SPGI | Exit | S&P GLOBAL INC | $0 | – | -2,225 | -100.0% | -1.13% | – |
| INTU | Exit | INTUIT | $0 | – | -1,965 | -100.0% | -1.18% | – |
| MSFT | Exit | MICROSOFT CORP | $0 | – | -3,263 | -100.0% | -1.25% | – |
| GOOG | Exit | ALPHABET INCcap stk cl c | $0 | – | -395 | -100.0% | -1.37% | – |
| ADXN | Exit | ADDEX THERAPEUTICS LTDsponsored ads | $0 | – | -265,940 | -100.0% | -1.68% | – |
| PSTH | Exit | PERSHING SQUARE TONTINE HLDG | $0 | – | -227,000 | -100.0% | -5.61% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-08-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| MOLECULAR TEMPLATES INC | 24 | Q2 2023 | 30.7% |
| STRONGBRIDGE BIOPHARMA PLC | 22 | Q3 2021 | 73.1% |
| GARRISON CAP INC | 18 | Q3 2020 | 9.9% |
| BERKSHIRE HATHAWAY INC DEL | 17 | Q3 2019 | 5.8% |
| EIGER BIOPHARMACEUTICALS INC | 17 | Q3 2022 | 1.7% |
| AGILE THERAPEUTICS INC | 16 | Q1 2018 | 55.5% |
| KALA PHARNACEUTICALS INC | 16 | Q4 2021 | 17.6% |
| CM FIN INC | 16 | Q1 2019 | 7.8% |
| SYNTA PHARMACEUTICALS CORP | 15 | Q2 2016 | 99.9% |
| CTI BIOPHARMA CORP | 14 | Q4 2021 | 8.7% |
View CAXTON CORP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Addex Therapeutics Ltd. | February 14, 2023 | 718,849 | 0.9% |
| Cardiff Oncology, Inc. | February 14, 2023 | 983,607 | 2.2% |
| Rezolute, Inc. | February 14, 2023 | 1,860,518 | 5.0% |
| Xeris Biopharma Holdings, Inc. | February 14, 2023 | 5,973,324 | 4.4% |
| CTI BIOPHARMA CORP | February 14, 2022 | 2,239,300 | 2.3% |
| Sierra Oncology, Inc. | February 14, 2022 | 1,119,322 | 7.0% |
| Strongbridge Biopharma plcSold out | January 05, 2022 | 0 | 0.0% |
| SUNESIS PHARMACEUTICALS INCSold out | February 16, 2021 | 0 | 0.0% |
| Alcentra Capital Corp | February 14, 2020 | 1,005,000 | 7.8% |
| Garrison Capital Inc. | February 14, 2020 | 1,223,096 | 7.6% |
View CAXTON CORP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-15 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| SC 13G/A | 2023-02-14 |
| SC 13G/A | 2023-02-14 |
| SC 13G/A | 2023-02-14 |
View CAXTON CORP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.